[{"data":1,"prerenderedAt":184},["ShallowReactive",2],{"report:en:board-declarations":3},{"schemaVersion":4,"locale":5,"direction":6,"routeId":7,"slug":8,"title":9,"source":10,"sourceSections":14},"1.0.0","en","ltr","board-declarations","governance\u002Fboard-declarations","Board Declarations",{"authority":11,"documentName":12,"sha256":13},"official-locale-idml","افالون فارما - التقرير السنوي english 2025 v3.20.indd","297bf7518216874132615aafd4aa637a92908ea1b50f6ee659ee25b8a368e0ea",[15],{"id":7,"title":16,"preview":17,"stories":20},"Board of Directors’ Declarations",[18,19],"The Company’s account records have been properly prepared. The internal control system has been established on sound foundations and implemented effectively. There are no doubts about the Company’s ability to continue as a going concern. The Company has no transactions or contracts with any related party. There are no competitive activities conducted by the Company or any of its business branches by any member of the Board of Directors. There is no conflict between the Audit Committee’s recommendations and the Board’s decisions regarding the appointment of the Company’s auditor and determination of its fees for the financial year 2025. The Company’s consolidated financial statements for the financial year 2025 have been prepared in accordance with the standards approved by the Saudi Organization for Certified Public Accountants (SOCPA). No shares or debt instruments have been issued to any subsidiary. The Company does not hold any interest in the voting shares of persons (other than the Company’s Board members, senior executives, and their relatives) who notified the Company of such holdings in accordance with Article 85 of the Securities Offering and Continuing Obligations Rules, nor any changes in such holdings during the last financial year. The Company does not own any class or number of convertible debt instruments, contractual securities, subscription rights memoranda, or similar rights issued or granted by the Company during the financial year. The Company does not possess any conversion or subscription rights under convertible debt instruments, contractual securities, subscription rights memoranda, or similar rights issued or granted by the Company. There are no arrangements or agreements under which any Board member or executive officer has waived any salaries or compensation. There are no arrangements or agreements under which any of the Company’s shareholders have waived their dividend rights. No investments or reserves have been established for the benefit of the Company’s employees. The Board of Directors has not issued any recommendation to replace the auditor before the end of their term. No treasury shares are owned. No transactions were conducted between the Company and any related party, nor any dealings between the Company and any related party. The internal auditor’s report did not include any reservations on the Company’s annual financial statements. There were no redemptions, purchases, or cancellations by the Company or any of its subsidiaries of any redeemable debt instruments. No interests, contractual securities, or subscription rights are held by the members of the Company’s Board of Directors, senior executives, or their relatives in the shares or debt instruments of the Company or any of its subsidiaries.","Reviewing and discussing the Company’s financial statements for the fiscal year ended 31 December 2025.",[21,109,135,160],{"id":22,"direction":23,"blocks":24},"ud30e","RightToLeftDirection",[25,70,84,95],{"id":26,"type":27,"text":28,"paragraphStyle":29,"runs":32},"ud30e:p0001","paragraph","      Board of Directors’ Declarations\n\n",{"id":30,"name":31},"ParagraphStyle\u002Fheadline bold 2","headline bold 2",[33,48,62],{"character_style":34,"text":37,"token_types":38,"overrides":40,"properties":42},{"id":35,"name":36},"CharacterStyle\u002F$ID\u002F[No character style]","[No character style]","      ",[39],"content",{"AppliedLanguage":41},"$ID\u002FEnglish: UK",[43],{"tag":44,"attributes":45,"text":47},"Leading",{"type":46},"unit","15",{"character_style":49,"text":50,"token_types":51,"overrides":53,"properties":54},{"id":35,"name":36},"Board of Directors’ Declarations\n",[39,52],"line_break",{"AppliedLanguage":41},[55,57],{"tag":44,"attributes":56,"text":47},{"type":46},{"tag":58,"attributes":59,"text":61},"AppliedFont",{"type":60},"string","Gotham",{"character_style":63,"text":64,"token_types":65,"overrides":66,"properties":67},{"id":35,"name":36},"\n",[52],{"AppliedLanguage":41},[68],{"tag":44,"attributes":69,"text":47},{"type":46},{"id":71,"type":27,"text":72,"paragraphStyle":73,"runs":76},"ud30e:p0002","The Board of Directors of the Company acknowledges the following:\n",{"id":74,"name":75},"ParagraphStyle\u002Fheader%3ahaidline main text فرعي 1","header:haidline main text فرعي 1",[77],{"character_style":78,"text":72,"token_types":79,"overrides":80,"properties":81},{"id":35,"name":36},[39,52],{},[82],{"tag":44,"attributes":83,"text":47},{"type":46},{"id":85,"type":27,"text":64,"paragraphStyle":86,"runs":87},"ud30e:p0003",{"id":74,"name":75},[88],{"character_style":89,"text":64,"token_types":90,"overrides":91,"properties":92},{"id":35,"name":36},[52],{},[93],{"tag":44,"attributes":94,"text":47},{"type":46},{"id":96,"type":27,"text":97,"paragraphStyle":98,"runs":101},"ud30e:p0004","The Company’s account records have been properly prepared.\nThe internal control system has been established on sound foundations and implemented effectively.\nThere are no doubts about the Company’s ability to continue as a going concern.\nThe Company has no transactions or contracts with any related party.\nThere are no competitive activities conducted by the Company or any of its business branches by any member of the Board of Directors.\nThere is no conflict between the Audit Committee’s recommendations and the Board’s decisions regarding the appointment of the Company’s auditor and determination of its fees for the financial year 2025.\nThe Company’s consolidated financial statements for the financial year 2025 have been prepared in accordance with the standards approved by the Saudi Organization for Certified Public Accountants (SOCPA).\nNo shares or debt instruments have been issued to any subsidiary.\nThe Company does not hold any interest in the voting shares of persons (other than the Company’s Board members, senior executives, and their relatives) who notified the Company of such holdings in accordance with Article 85 of the Securities Offering and Continuing Obligations Rules, nor any changes in such holdings during the last financial year.\nThe Company does not own any class or number of convertible debt instruments, contractual securities, subscription rights memoranda, or similar rights issued or granted by the Company during the financial year.\nThe Company does not possess any conversion or subscription rights under convertible debt instruments, contractual securities, subscription rights memoranda, or similar rights issued or granted by the Company.\nThere are no arrangements or agreements under which any Board member or executive officer has waived any salaries or compensation.\nThere are no arrangements or agreements under which any of the Company’s shareholders have waived their dividend rights.\nNo investments or reserves have been established for the benefit of the Company’s employees.\nThe Board of Directors has not issued any recommendation to replace the auditor before the end of their term.\nNo treasury shares are owned.\nNo transactions were conducted between the Company and any related party, nor any dealings between the Company and any related party.\nThe internal auditor’s report did not include any reservations on the Company’s annual financial statements.\nThere were no redemptions, purchases, or cancellations by the Company or any of its subsidiaries of any redeemable debt instruments.\nNo interests, contractual securities, or subscription rights are held by the members of the Company’s Board of Directors, senior executives, or their relatives in the shares or debt instruments of the Company or any of its subsidiaries.\n",{"id":99,"name":100},"ParagraphStyle\u002Fmain text with bullets number","main text with bullets number",[102],{"character_style":103,"text":97,"token_types":104,"overrides":105,"properties":106},{"id":35,"name":36},[39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52,39,52],{},[107],{"tag":44,"attributes":108,"text":47},{"type":46},{"id":110,"direction":23,"blocks":111},"u12853",[112,124],{"id":113,"type":27,"text":114,"paragraphStyle":115,"runs":118},"u12853:p0001","The Company’s Financial Statements for the Fiscal Year Ended 31 December 2025\n",{"id":116,"name":117},"ParagraphStyle\u002Fheader%3ahaidline main text رئيسي ","header:haidline main text رئيسي ",[119],{"character_style":120,"text":114,"token_types":121,"overrides":122,"properties":123},{"id":35,"name":36},[39,52],{},[],{"id":125,"type":27,"text":19,"paragraphStyle":126,"runs":129},"u12853:p0002",{"id":127,"name":128},"ParagraphStyle\u002Fmain text group%3amain text english","main text group:main text english",[130],{"character_style":131,"text":19,"token_types":132,"overrides":133,"properties":134},{"id":35,"name":36},[39],{},[],{"id":136,"direction":137,"blocks":138},"u1286e","LeftToRightDirection",[139],{"id":140,"type":27,"text":141,"paragraphStyle":142,"runs":145},"u1286e:p0001","The Company’s Financial Statements for the Fiscal Year Ended 31 December 2025",{"id":143,"name":144},"ParagraphStyle\u002Fheader%3amain text med blue ابيض","header:main text med blue ابيض",[146],{"character_style":147,"text":141,"token_types":148,"overrides":149,"properties":153},{"id":35,"name":36},[39],{"AppliedLanguage":150,"FontStyle":151,"PointSize":152},"$ID\u002FEnglish: USA","Medium","11",[154,158],{"tag":44,"attributes":155,"text":157},{"type":156},"enumeration","Auto",{"tag":58,"attributes":159,"text":61},{"type":60},{"id":161,"direction":23,"blocks":162},"u11ed",[163],{"id":164,"type":27,"text":165,"paragraphStyle":166,"runs":169},"u11ed:p0001","www.avalonpharmaceutical.com",{"id":167,"name":168},"ParagraphStyle\u002F$ID\u002FNormalParagraphStyle","NormalParagraphStyle",[170],{"character_style":171,"text":165,"token_types":172,"overrides":173,"properties":177},{"id":35,"name":36},[39],{"FillColor":174,"FontStyle":175,"Tracking":176},"Color\u002Fprimary","Light","280",[178,181],{"tag":44,"attributes":179,"text":180},{"type":46},"20",{"tag":58,"attributes":182,"text":183},{"type":60},"Helvetica",1790446650191]